AI Article Synopsis
- B cell precursor acute lymphoblastic leukemia (BCP-ALL) is hard to treat because leukemia cells are protected by the bone marrow environment, making them resistant to chemotherapy.
- This study investigates using bortezomib, a drug that disrupts the interaction between BCP-ALL cells and bone marrow mesenchymal stem cells (BM-MSCs), which help the leukemia cells survive.
- The results show that combining bortezomib with doxorubicin can improve treatment outcomes by reducing leukemia cells and extending survival in mouse models, highlighting a potential new approach to tackle BCP-ALL.
Article Abstract
The poor prognosis of adults with B cell precursor acute lymphoblastic leukemia (BCP-ALL) is attributed to leukemia cells that are protected by the bone marrow (BM) microenvironment. In the present study, we explored the pharmacological targeting of mesenchymal stromal/stem cells in BM (BM-MSCs) to eliminate chemoresistant BCP-ALL cells. Human BCP-ALL cells (NALM-6 cells) that adhered to human BM-MSCs (NALM-6/Ad) were highly resistant to multiple anti-cancer drugs, and exhibited pro-survival characteristics, such as an enhanced Akt/Bcl-2 pathway and increased populations in the G0 and G2/S/M cell cycle stages. Bortezomib, a proteasome inhibitor, interfered with adhesion between BM-MSCs and NALM-6 cells and up-regulated the matricellular protein SPARC (secreted protein acidic and rich in cysteine) in BM-MSCs, thereby reducing the NALM-6/Ad population. Inhibition of SPARC expression in BM-MSCs using a small interfering RNA enhanced adhesion of NALM-6 cells. Conversely, recombinant SPARC protein interfered with adhesion of NALM-6 cells. These results suggest that SPARC disrupts adhesion between BM-MSCs and NALM-6 cells. Co-treatment with bortezomib and doxorubicin prolonged the survival of BCP-ALL xenograft mice, with a significant reduction of leukemia cells in BM. Our findings demonstrate that bortezomib contributes to the elimination of BCP-ALL cells through disruption of their adhesion to BM-MSCs, and offer a novel therapeutic strategy for BCP-ALL through targeting of BM-MSCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-016-2169-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals.
Front Immunol
December 2024
State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Background: Chimeric antigen receptor (CAR) engineered natural killer (NK) cells exhibit advantages such as MHC-independent recognition and strong anti-tumor functions. However, allogeneic CAR-NK cells derived from human tissues are heterogeneous and susceptible to clearance by hosts.
Methods: We generated a B2M knockout, HLA-E and CD19 CAR ectopic expressing embryonic stem cell (ESC) line, which differentiated normally and gave rise to homogeneous CD19 CAR-NK (CD19 CAR-UiNK) cells using an organoid aggregate induction method.
n-3 polyunsaturated fatty acids enhanced efficacy of cytarabine in iron-overloaded NALM-6 cells via apoptotic and oxidative pathways.
Toxicol In Vitro
March 2025
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. Electronic address:
Despite progress in treating acute lymphoblastic leukemia (ALL), the adverse effects of chemotherapy toxicity and iron overload from transfusions continue to affect patients' quality of life. Polyunsaturated fatty acids (PUFAs) exhibit both antitumor and anti-inflammatory properties in leukemia. This study investigated the influence of n-3 PUFA on the efficacy of cytarabine in cells with iron overload.
View Article and Find Full Text PDFQuercetin exhibits cytotoxicity in cancer cells by inducing two-ended DNA double-strand breaks.
Biochem Biophys Res Commun
December 2024
Graduate School of Science and Technology, Gunma University, Kiryu, 376-8515, Japan; Graduate School of Nanobioscience, Yokohama City University, Yokohama, 236-0027, Japan; Gunma University Center for Food and Science and Wellness, Gunma University, Kiryu, 376-8515, Japan. Electronic address:
Article Synopsis
- Quercetin, a flavonoid with antioxidant properties, can induce DNA double-strand breaks (DSBs) in a concentration-dependent manner, but the exact mechanism behind this effect is still unclear.
- The study used HeLa cells and gene-knockout cell lines to investigate that quercetin does not primarily involve DNA topoisomerase II (Top2) in inducing DSBs; instead, a transient accumulation of reactive oxygen species (ROS) is linked to this process.
- The DSBs caused by quercetin are mainly repaired through non-homologous end-joining and homologous recombination, suggesting it could be used as a radiomimetic agent with effects similar to X-ray exposure.
The impact of Trifolium pratense extract on apoptosis and autophagy in NALM-6 cells: implications for B-ALL intervention.
Med Oncol
October 2024
Division of Hematology and Blood Bank, Department of Laboratory Science, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran.
B-cell acute lymphoblastic leukemia (B-ALL), a prevalent malignancy predominantly affecting children, poses challenges such as drug resistance and cytotoxicity despite available treatment methods. The persistence of these challenges underscores the necessity for innovative therapeutic approaches to enhance efficacy. Natural compounds derived from plants, recognized for their potential to inhibit cancer cell growth, have drawn attention.
View Article and Find Full Text PDFEvaluation of ferroptosis-based anti-leukemic activities of ZnO nanoparticles synthesized by a green route against Pre-B acute lymphoblastic leukemia cells (Nalm-6 and REH).
Heliyon
September 2024
Student Research Committee, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Article Synopsis
- The study introduces a practical method for creating Zinc Oxide nanoparticles (ZnO NPs) that can potentially combat leukemia by inducing ferroptosis, a form of programmed cell death.
- Using a natural extract, the researchers synthesized and characterized ZnO NPs, and tested their effects on leukemic and normal cells at various concentrations over 24 and 48 hours.
- Results showed that ZnO NPs successfully reduced leukemic cell survival without harming normal cells, indicating their potential as a complementary treatment in leukemia therapies by altering iron levels and increasing oxidative stress in cancer cells.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!